Courier Health Secures $50M Series B to Advance AI-Powered Patient Engagement Platform for Specialty Therapies
核心洞察
Courier Health (搜索) raised $50 million in Series B funding led by Oak HC/FT (搜索) to scale its AI-powered patient experience platform designed specifically for life sciences commercial teams.
The platform addresses critical gaps in specialty therapy adherence, where 30% of patients never start prescribed specialty drugs and 70% discontinue within the first few months.
Companies using Courier Health (搜索)'s technology have achieved gains exceeding 15% in patient start rates, a 67% reduction in time-to-start, and seven-fold increases in team productivity.
Courier Health (搜索), a New York-based health technology company, has secured $50 million in Series B funding led by Oak HC/FT (搜索), with participation from existing investors Norwest Venture Partners (搜索) and Work-Bench (搜索). The funding round brings the company's total capital raised to $70.5 million and will support the expansion of its AI-powered patient engagement platform designed specifically for life sciences commercial teams.
Addressing Critical Gaps in Specialty Therapy Adherence
The funding comes as the life sciences industry faces a significant challenge in patient support infrastructure. Despite breakthrough advances in specialty therapies (搜索), roughly 30% of patients who receive a specialty drug prescription never start that therapy, and 70% discontinue within the first few months. This disconnect stems from siloed data, manual processes, and disconnected systems that leave biopharma commercial teams operating without a unified view of the patient journey.
"The life sciences industry has seen tremendous clinical advancements, but as therapies have gotten more specialized and patient journeys more complex, the technology enabling the critical commercial teams responsible for supporting patients and providers have fallen behind," said Danny Sigurdson, Founder and CEO of Courier Health (搜索).
Platform Performance and Market Impact
Courier Health (搜索)'s purpose-built patient experience platform connects disparate data sources and applies AI to proactively surface at-risk patients while coordinating the full journey from prescription through long-term adherence. Companies using the platform have recorded significant improvements in key metrics:
- Gains exceeding 15% in patient start rates
- 67% reduction in time-to-start
- Seven-fold increases in team productivity
- Double-digit improvements in 6-month persistency
The company has experienced rapid growth, quadrupling the number of therapies managed on its platform in 2025 and more than doubling its headcount to meet accelerating demand.
Technology and Competitive Positioning
The platform integrates data across systems and leverages AI at every layer to orchestrate more seamless patient experiences. This enables biopharma commercial teams to more efficiently and effectively engage stakeholders across the patient journey to drive better health outcomes. The system is designed to help Field Access and Patient Services teams prioritize their day and automate processes at scale.
Courier Health (搜索) positions itself as a modern alternative in the life sciences CRM space, competing with established platforms such as Veeva Vault CRM (搜索), Salesforce Life Sciences Cloud (搜索), and Microsoft Dynamics 365 (搜索). The company's platform is licensed to biopharma companies and supported entirely in-house by the New York-based team.
Future Development Plans
The new funding will support continued investment in product development and agentic AI capabilities. Over the next six months, the company plans to develop additional AI agents designed and trained specifically for the life sciences industry that can work autonomously to handle tasks such as intake processing, benefits checks, and responding to information requests.
"We remain focused on scaling our platform and AI advantage, attracting top-notch talent, and growing our customer base," Sigurdson noted. The company is actively hiring across almost every department and plans to move into new office space while continuing to challenge the status quo of how biopharma commercial teams operate.
Market Opportunity
The addressable market includes hundreds of biopharma manufacturers, thousands of specialty therapies (搜索) on the market or in development, and hundreds of millions of patients and families who depend on these medicines. The company remains focused on enabling and empowering commercial teams with the technology they need to be more efficient and effective while improving the overall patient experience.
Following a $16.5 million Series A round in 2024, this latest funding round underscores growing investor confidence in tools that bring a more patient-centric approach to commercial operations in the pharmaceutical industry.